Abstract
Non-alcoholic steatohepatitis (NASH) is a disease that compromises hepatic function and the capacity to metabolize numerous drugs. Aryl hydrocarbon receptor (AhR), constitutive androstane receptor (CAR), pregnane X receptor (PXR), peroxisome proliferator-activated receptor alpha (PPARα), and nuclear factor-E2 related factor 2 (Nrf2) are xenobiotic activated transcription factors that regulate induction of a number of drug metabolizing enzymes (DMEs). The purpose of the current study was to determine whether experimental NASH alters the xenobiotic activation of these transcription factors and induction of downstream DME targets Cyp1A1, Cyp2B10, Cyp3A11, Cyp4A14 and NAD(P)H:quinone oxidoreductase 1 (Nqo1), respectively. Mice fed normal rodent chow or methionine-choline-deficient (MCD) diet for 8 weeks were then treated with microsomal enzyme inducers β-naphoflavone (BNF), 1,4-bis-[2-(3,5-dichloropyridyloxy)] benzene (TCPOBOP), pregnenolone-16α-carbonitrile (PCN), clofibrate (CFB) or oltipraz (OPZ), known activators of AhR, CAR, PXR, PPARα and Nrf2, respectively. Results of this study show that (1) Hepatic PXR mRNA levels were significantly increased (1.4-fold) in mice fed MCD diet, while AhR, CAR, PPARα and Nrf2 were not affected. (2) The MCD diet did not alter hepatic inducibility of Cyp1A1, Cyp2B10, Cyp3A11 mRNA levels by their respective microsomal inducers. (3) Constitutive levels of Cyp4A14 mRNA were significantly increased in mice fed the MCD diet, yet further induction by clofibrate was not observed. (4) Hepatic Nqo1 mRNA levels were significantly increased by the MCD diet; however, additional induction of Nqo1 was still achievable following treatment with the Nrf2 activator OPZ.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anakk S, Kalsotra A, Kikuta Y, Huang W, Zhang J, Staudinger JL, Moore DD, Strobel HW (2004) CAR/PXR provide directives for Cyp3a41 gene regulation differently from Cyp3a11. Pharmacogenomics J 4:91–101
Browning JD, Horton JD (2004) Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114:147–152
Chitturi S, Farrell GC (2001) Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 21:27–41
Elias E, Mills CO (2007) Coordinated defence and the liver. Clin Med 7:180–184
Farrell GC, Cooksley WG, Hart P, Powell LW (1978) Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism. Gastroenterology 75:580–588
Fisher CD, Augustine LM, Maher JM, Nelson DM, Slitt AL, Klaassen CD, Lehman-McKeeman LD, Cherrington NJ (2007) Induction of drug-metabolizing enzymes by garlic and allyl sulfide compounds via activation of constitutive and rostane receptor and nuclear factor E2-related factor 2. Drug Metab Dispos 35:995–1000
Harmsen S, Meijerman I, Beijnen JH, Schellens JH (2007) The role of nuclear receptors in pharmacokinetic drug–drug interactions in oncology. Cancer Treat Rev 33:369–380
Honkakoski P, Negishi M (2000) Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J 347:321–337
Karpen SJ (2002) Nuclear receptor regulation of hepatic function. J Hepatol 36:832–850
Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM, Edwards PA (2002) Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane x receptor, farnesoid x-activated receptor, and constitutive androstane receptor. J Biol Chem 277:2908–2915
Klaassen CD, Slitt AL (2005) Regulation of hepatic transporters by xenobiotic receptors. Curr Drug Metab 6:309–328
Koike C, Moore R, Negishi M (2007) Extracellular signal-regulated kinase is an endogenous signal retaining the nuclear constitutive active/androstane receptor (CAR) in the cytoplasm of mouse primary hepatocytes. Mol Pharmacol 71:1217–1221
Lickteig AJ, Fisher CD, Augustine LM, Cherrington NJ (2007) Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis. J Biochem Mol Toxicol 21:216–220
McMahon M, Itoh K, Yamamoto M, Chanas SA, Henderson CJ, McLellan LI, Wolf CR, Cavin C, Hayes JD (2001) The cap’n’collar basic leucine zipper transcription factor Nrf2 (NF-E2 P45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res 61:3299–3307
Nagasawa T, Inada Y, Nakano S, Tamura T, Takahashi T, Maruyama K, Yamazaki Y, Kuroda J, Shibata N (2006) Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 536:182–191
Neuschwander-Tetri BA, Caldwell SH (2003) Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37:1202–1219
Pascussi JM, Gerbal-Chaloin S, Drocourt L, Assenat E, Larrey D, Pichard-Garcia L, Vilarem MJ, Maurel P (2004) Cross-talk between xenobiotic detoxication and other signalling pathways: clinical and toxicological consequences. Xenobiotica 34:633–664
Petrick JS, Klaassen CD (2007) Importance of hepatic induction of constitutive androstane receptor (CAR) and other transcription factors that regulate xenobiotic metabolism and transport. Drug Metab Dispos 35(10):1806–1815
Pustylnyak VO, Lebedev AN, Gulyaeva LF, Lyakhovich VV, Slynko NM (2007) Comparative study of CYP2B induction in the liver of rats and mice by different compounds. Life Sci 80:324–328
Qatanani M, Moore DD (2005) CAR, the continuously advancing receptor, in drug metabolism and disease. Curr Drug Metab 6:329–339
Reynaert H, Geerts A, Henrion J (2005) Review article: the treatment of non-alcoholic steatohepatitis with thiazolidinediones. Aliment Pharmacol Ther 22:897–905
Tanaka N, Aoyama T (2006) PPAR and NASH. Nippon Rinsho 64:1089–1094
Timsit YE, Negishi M (2007) CAR and PXR: the xenobiotic-sensing receptors. Steroids 72:231–246
Venugopal R, Jaiswal AK (1996) Nrf1 and Nrf2 positively and C-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H: quinone oxidoreductase1 gene. Proc Natl Acad Sci USA 93:14960–14965
Waxman DJ (1999) P450 Gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 369:11–23
Westphal JF, Brogard JM (1997) Drug administration in chronic liver disease. Drug Saf 17:47–73
Wilkinson GR (1997) The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans. Adv Drug Deliv Rev 27:129–159
Yang LQ, Li SJ, Cao YF, Man XB, Yu WF, Wang HY, Wu MC (2003) Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases. World J Gastroenterol 9:359–363
Zandbergen F, Plutzky J (2007) PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta 1771(8):972–982
Acknowledgments
We are grateful to Ms. Lisa Beilke and Mr. Matthew Merrell for their reading of the manuscript. The project described was supported by NIH grants DK068039, ES06694, and AT002842. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Diabetes Digestive and Kidney Diseases, the National Institute for Environmental Health Sciences, the National Center for Complementary & Alternative Medicine of the National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Additional information
Craig D. Fisher and Jonathan P. Jackson contributed equally to this manuscript.
Rights and permissions
About this article
Cite this article
Fisher, C.D., Jackson, J.P., Lickteig, A.J. et al. Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Arch Toxicol 82, 959–964 (2008). https://doi.org/10.1007/s00204-008-0312-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-008-0312-z